ArticleFrontiers in pharmacology2026
Advanced hybrid-stabilized cinacalcet nanocrystals for enhanced oral bioavailability: formulation and integrated
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cinacalcet (CINA), a Biopharmaceutics Classification System (BCS) Class IV drug, exhibits limited oral bioavailability due to poor aqueous solubility and low intestinal permeability. We aimed to mechanistically enhance the oral bioavailability of CINA through the development of advanced hybrid-stabilized nanocrystals (HNCs) prepared through high-speed homogenization. Methods: A dual-stabilization strategy was implemented, combining a steric stabilizer (polyvinylpyrrolidone K90 or Pluronic® F-127) with a dispersing stabilizer (Tween® 80) to synergistically control nanocrystal formation, surface properties, and colloidal stability. A 2 Results: Numerical optimization identified an optimal formulation exhibiting a PS of 193.44 nm, a PDI of 0.34, and an SS of 2.04 mg/mL, corresponding to a 1.8-fold increase compared with unprocessed CINA (1.10 ± 0.02 mg/mL). Furthermore, the optimized formula exhibited a zeta potential (ZP) of -24.25 ± 0.64 mV, indicating good colloidal stability. Transmission electron microscopy confirmed the formation of discrete, uniformly distributed nanocrystals with well-defined nanoscale morphology. The optimized formulation demonstrated markedly enhanced dissolution behavior in simulated gastric (pH 1.2) and intestinal (pH 6.8) media, alongside satisfactory zeta potential and physical stability. Conclusion: Collectively, these findings highlight hybrid-stabilized nanocrystals as a promising strategy for improving the oral bioavailability of poorly soluble and poorly permeable drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.